This site is intended only for healthcare professionals resident in the Republic of Ireland
Over 10 years, clinicians’ experience of INLYTA® has demonstrated the safety and tolerability profile of INLYTA® observed in clinical trials.1–5
The short half-life of INLYTA® ensures that it is cleared more quickly following dose interruptions/discontinuations:1,2
||INLYTA® (n=359)||Sorafenib (n=355)|
|All grades (%)||≥ Grade 3 (%)||All grades (%)||≥ Grade 3 (%)|
For some patients, taking a short break (e.g. 1–2 days) before restarting INLYTA® may help AEs to resolve quickly.1,6
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023